StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)

Close on Nov 18, 2026Market cap $291.16MP/E –Yield –

SAB Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

SAB Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$71.82M. For fiscal 2025 it was -$48.95M. The highest annual figure on record is $20.56M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.95M–
FY2024Dec 31, 2024-$42.91M–
FY2023Dec 31, 2023-$38.08M–
FY2022Dec 31, 2022-$28.92M–
FY2021Dec 31, 2021-$13.39M-165.2%
FY2020Dec 31, 2020$20.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.38M–
Q1 FY2026Mar 31, 2026-$20.00M–
Q4 FY2025Dec 31, 2025-$15.77M–
Q3 FY2025Sep 30, 2025-$12.68M–
Q2 FY2025Jun 30, 2025-$9.73M–
Q1 FY2025Mar 31, 2025-$10.77M–
Q4 FY2024Dec 31, 2024-$10.01M–
Q3 FY2024Sep 30, 2024-$11.31M–
Q2 FY2024Jun 30, 2024-$10.20M–
Q1 FY2024Mar 31, 2024-$11.39M–
Q4 FY2023Dec 31, 2023-$18.87M–
Q3 FY2023Sep 30, 2023-$5.32M–
Q2 FY2023Jun 30, 2023-$6.48M–
Q1 FY2023Mar 31, 2023-$7.40M–
Q4 FY2022Dec 31, 2022-$7.86M–
Q3 FY2022Sep 30, 2022-$7.81M–
Q2 FY2022Jun 30, 2022-$6.54M–
Q1 FY2022Mar 31, 2022-$6.71M-924.1%
Q4 FY2021Dec 31, 2021-$7.34M–
Q3 FY2021Sep 30, 2021-$3.99M–
Q2 FY2021Jun 30, 2021-$2.87M–
Q1 FY2021Mar 31, 2021$813.92K–

More SAB Biotherapeutics figures

See a number that looks wrong?